-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Guangzhou Huajin Pharmaceutical Technology .
, L.
(hereinafter referred to as: Huajin Pharmaceutical) announced the completion of the Pre-B round of financing at the level of tens of millions of dolla.
This round of financing was led by Wenzheng Assets, followed by Xenuo Investment and Huarui Fu.
Investment, the funds raised in this round of financing will be used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of SGN1, the world’s first tumor-targeted amino acid metabolic pathway-regulated oncolytic bacterial biological product, and to accelerate its globalization Clinical pipeline proce.
In the field of tumor treatment, there are currently more monoclonal antibodies, but traditional monoclonal antibodies mainly play a therapeutic role by binding a single specific epito.
However, diseases usually have multiple signaling pathwa.
By blocking multiple signaling pathways, the achieve more effective treatme.
Based on the disadvantages of monoclonal antibody therapy, more and more new antibody drugs are being developed, and oncolytic bacterial therapy is one of th.
In recent years, the global tumor drug market has grown rapidly and the market prospect is very bro.
Coupled with the continuous development and progress of oncolytic carrier technology, oncolytic bacteria are also considered by the industry as an important research direction for cancer immunotherapy in the futu.
At present, many domestic and foreign companies have deployed In this track, the industry believes that the emerging blue ocean market of oncolytic bacteria has begun to take shape and is waiting to be further explored and develop.
According to reports, SGN1 was independently developed by Huajin Pharmaceutical and is the world's first genetically engineered biological product that can accurately target and rapidly dissolve tumors in the clinical trial sta.
SGN1 carries a specific methionine hydrolase through an attenuated Salmonella vector to deprive tumors of essential amino acids required for tumor growth, thereby killing tumors and preventing tumor spre.
The product can not only direct intratumoral administration and interventional administration, but also can be administered intravenously to treat non-superficial tumors and in vivo metastas.
SGN1 will open up a new therapeutic field of tumor-targeted amino acid metabolism pathway regulation therapy and bring new solutions to the treatment of malignant tumo.
Huajin Pharmaceutical owns the complete intellectual property rights and global rights and interests of SGN1, has applied for PCT and nearly 50 invention patents from various countries around the world, and obtained 18 authorizatio.
According to the results of clinical trials (IITs) initiated by researchers in many domestic hospitals, SGN1 showed high performance in the single-agent treatment of liver cancer, lung cancer, sarcoma, melanoma, nasopharyngeal cancer, cervical cancer and other malignant tumo.
It has obvious clinical efficacy and good safe.
It is reported that after successfully passing the two new drug clinical trial applications (IND) approvals of the US FDA, Huajin Pharmaceutical has successively launched Phase I/IIa registration clinical trials of SGN1 intravenous administration and intratumoral administration in several clinical trial centers in the United Stat.
, and submitted more than two Orphan Drug Designation applications for SGN1 in the treatment of malignant tumor indications to the US FDA within the ye.
In addition, the company is in Taiwan, China and plans to conduct IND applications for SGN1 in China, South Korea, Australia and other countries and regions, with a view to conducting a global multi-center clinical trial of SGN1 in the treatment of malignant solid tumo.
According to the data, Huajin Pharmaceutical is a biomedical technology company dedicated to the field of cancer and tumor treatme.
The company is mainly engaged in the research and development of new anti-cancer dru.
It has mastered a series of new biological treatment technologies for malignant tumors, and has corresponding independent intellectual property righ.
Since its establishment, the company has successively received multiple rounds of investment from institutions such as Share Investment, CICC Qide Fund under CICC Capital, and Wenzheng Asse.
Up to now, the company has completed various rounds of financing with a cumulative amount of tens of millions of dolla.
Click to enter the exhibition page
, L.
(hereinafter referred to as: Huajin Pharmaceutical) announced the completion of the Pre-B round of financing at the level of tens of millions of dolla.
This round of financing was led by Wenzheng Assets, followed by Xenuo Investment and Huarui Fu.
Investment, the funds raised in this round of financing will be used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of SGN1, the world’s first tumor-targeted amino acid metabolic pathway-regulated oncolytic bacterial biological product, and to accelerate its globalization Clinical pipeline proce.
In the field of tumor treatment, there are currently more monoclonal antibodies, but traditional monoclonal antibodies mainly play a therapeutic role by binding a single specific epito.
However, diseases usually have multiple signaling pathwa.
By blocking multiple signaling pathways, the achieve more effective treatme.
Based on the disadvantages of monoclonal antibody therapy, more and more new antibody drugs are being developed, and oncolytic bacterial therapy is one of th.
In recent years, the global tumor drug market has grown rapidly and the market prospect is very bro.
Coupled with the continuous development and progress of oncolytic carrier technology, oncolytic bacteria are also considered by the industry as an important research direction for cancer immunotherapy in the futu.
At present, many domestic and foreign companies have deployed In this track, the industry believes that the emerging blue ocean market of oncolytic bacteria has begun to take shape and is waiting to be further explored and develop.
According to reports, SGN1 was independently developed by Huajin Pharmaceutical and is the world's first genetically engineered biological product that can accurately target and rapidly dissolve tumors in the clinical trial sta.
SGN1 carries a specific methionine hydrolase through an attenuated Salmonella vector to deprive tumors of essential amino acids required for tumor growth, thereby killing tumors and preventing tumor spre.
The product can not only direct intratumoral administration and interventional administration, but also can be administered intravenously to treat non-superficial tumors and in vivo metastas.
SGN1 will open up a new therapeutic field of tumor-targeted amino acid metabolism pathway regulation therapy and bring new solutions to the treatment of malignant tumo.
Huajin Pharmaceutical owns the complete intellectual property rights and global rights and interests of SGN1, has applied for PCT and nearly 50 invention patents from various countries around the world, and obtained 18 authorizatio.
According to the results of clinical trials (IITs) initiated by researchers in many domestic hospitals, SGN1 showed high performance in the single-agent treatment of liver cancer, lung cancer, sarcoma, melanoma, nasopharyngeal cancer, cervical cancer and other malignant tumo.
It has obvious clinical efficacy and good safe.
It is reported that after successfully passing the two new drug clinical trial applications (IND) approvals of the US FDA, Huajin Pharmaceutical has successively launched Phase I/IIa registration clinical trials of SGN1 intravenous administration and intratumoral administration in several clinical trial centers in the United Stat.
, and submitted more than two Orphan Drug Designation applications for SGN1 in the treatment of malignant tumor indications to the US FDA within the ye.
In addition, the company is in Taiwan, China and plans to conduct IND applications for SGN1 in China, South Korea, Australia and other countries and regions, with a view to conducting a global multi-center clinical trial of SGN1 in the treatment of malignant solid tumo.
According to the data, Huajin Pharmaceutical is a biomedical technology company dedicated to the field of cancer and tumor treatme.
The company is mainly engaged in the research and development of new anti-cancer dru.
It has mastered a series of new biological treatment technologies for malignant tumors, and has corresponding independent intellectual property righ.
Since its establishment, the company has successively received multiple rounds of investment from institutions such as Share Investment, CICC Qide Fund under CICC Capital, and Wenzheng Asse.
Up to now, the company has completed various rounds of financing with a cumulative amount of tens of millions of dolla.
Click to enter the exhibition page
